DIANA MIMS: Open Payments
NPI 1598469066 · GREENWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$966 in 44 payments from 11 companies in 2025. Trend: 2023 $294 · 2024 $353 · 2025 $966
Food & beverage: $753Education: $213
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $318 |
| E.R. Squibb & Sons, L.L.C. | 11 | $179 |
| Axsome Therapeutics, Inc. | 8 | $136 |
| Neurocrine BioSciences, Inc. | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Supernus Pharmaceuticals, Inc. | 3 | $58 |
| Lundbeck LLC | 3 | $50 |
| ABBVIE INC. | 1 | $24 |
| Alkermes, Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
Products named: COBENFY, Auvelity, AUSTEDO XR, INGREZZA, CAPLYTA, Qelbree, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across MS — which companies pay providers there.
